HealthLynked Launches National Initiative to Accelerate Medical Discovery Through Patient Participation and Strategic Pharma Partnerships

Rhea-AI Summary

HealthLynked (OTCQB: HLYK) has announced a nationwide initiative to accelerate medical research by connecting patients with pharmaceutical and biotech partners through its technology platform. The company, with over 1 million registered members, will roll out research collaboration programs between Q3 2025 and January 2026.

The initiative includes five key partnership tracks: cohort finder & feasibility, recruitment & eConsent, ePROs & RWE generation, signal & safety monitoring, and natural history & rare disease registries. The platform is supported by ARi, an AI healthcare agent built with OpenAI technologies, to analyze patient data and identify trends. Patients can join for free or access premium features for $12/month.

Positive

• Large established user base of over 1 million registered members
• Multiple revenue streams through pharma partnerships and premium memberships
• Integration of advanced AI technology (ARi) for data analysis
• Structured approach with 5 distinct partnership tracks for research collaboration

Negative

• Extended rollout timeline spanning 6 months before full availability
• Trading on OTCQB market rather than major exchanges
• No specific partnership agreements announced yet
• Potential data privacy and security risks handling sensitive health information

HealthLynked Launches National Initiative to Accelerate Medical Discovery Through Patient Participation and Strategic Pharma Partnerships

NAPLES, Fla., Aug. 5, 2025 /PRNewswire/ --  HealthLynked Corp. (OTCQB: HLYK), a healthcare technology company connecting patients, providers, and data, today announced a nationwide initiative to make patients central collaborators in medical research—and to help pharmaceutical, biotech, and academic partners accelerate discovery using HealthLynked's patient network and AI capabilities. With over 1 million registered members, HealthLynked can enable large-scale, consented participation to advance prevention, earlier diagnosis, and more effective treatments. These programs will be rolled out over the next six months as HealthLynked formalizes research partnerships, with initial capabilities beginning in Q3 2025, expanded modules in Q4 2025, and full program availability targeted by January 2026.

Founded by physician and healthcare entrepreneur Dr. Michael Dent, who also founded NeoGenomics Laboratories, HealthLynked was created to empower patients and speed the search for cures for life-threatening diseases and cancers. Today's initiative advances that mission by opening clearer, simpler on-ramps for patients to contribute—and by offering research partners structured programs to generate high-quality real-world evidence.

"Most people want to help cure diseases but have very few practical opportunities to do so," said Dr. Dent, CEO of HealthLynked. "By creating a free profile, patients can securely share their health history, opt into studies, and get matched to relevant trials—while our partners gain the real-world evidence they need to move faster from hypothesis to impact."

How Patients Help—and Benefit

Through the free HealthLynked profile, patients can:

• Enter medical history (conditions, medications, procedures, family history) and opt in to research participation.
• Receive personalized notifications—such as trial matches, safety alerts, recall notices, and trend-based insights tied to their health history.
• Contribute patient-reported outcomes (ePROs) and longitudinal updates that help researchers understand disease progression and treatment effectiveness in real-world settings.

All research activity is consent-driven, with data de-identified or aggregated when appropriate, and studies conducted under applicable privacy and ethics requirements (including HIPAA and IRB oversight where required).

Partner Programs for Pharma, Biotech, and Academia

HealthLynked is launching structured collaboration tracks to support the full research lifecycle:

1.  Cohort Finder & Feasibility – Rapid identification of consented patient cohorts meeting complex inclusion/exclusion criteria; feasibility assessments across geographies.

2.  Recruitment & eConsent – Digital outreach, screening, and IRB-aligned eConsent workflows; optional decentralized trial support.

3.  ePROs & RWE Generation – Collection of longitudinal patient-reported outcomes and integration of real-world data to inform endpoints, labeling, and health-economics studies.

4.  Signal & Safety Monitoring – Post-marketing surveillance, device and medication safety signal detection, and recall communication to relevant patient segments.

5.  Natural History & Rare Disease Registries – Patient-powered registries to understand disease trajectories and support companion diagnostic development.

Six-Month Rollout: These collaboration tracks will be phased in over the next six months as HealthLynked develops and finalizes research partnerships with pharmaceutical sponsors, biotech firms, and academic medical centers—starting in Q3 2025, expanding in Q4 2025, with general availability targeted by January 2026.

ARi: HealthLynked's AI Healthcare Agent

HealthLynked's ARi—built with advanced OpenAI technologies—helps synthesize patient-contributed data to highlight population trends and individual risk signals. ARi aids in feasibility modeling, cohort refinement, and predictive insights that can shorten timelines for study design, trial recruitment, and evidence development. For patients, ARi supports personalized health alerts based on emerging patterns and their own medical history.

A Call to Action

Patients: Join for free, contribute to research, and receive informed insights about your health.
Researchers & Sponsors: Partner with HealthLynked to speed feasibility, recruitment, and RWE generation. Program access will expand throughout the next six months as partnerships are executed.

For those wishing to make an even greater impact, HealthLynked offers premium memberships at $12/month, including enhanced features, discounted telemedicine services, and priority access to the provider network.

"Imagine if everyone affected by cancer, Alzheimer's, or heart disease could actively participate in finding a cure," added Dr. Dent. "That's the network we're building—a national, and eventually global, research engine powered by patients."

Partnership Opportunities

Organizations interested in joining HealthLynked in its mission to accelerate medical discovery through collaboration and innovation can learn more and connect with the company at www.hlykgroup.com.

About HealthLynked Corp.
HealthLynked Corp. is transforming the future of healthcare through a cloud-based platform that connects patients, physicians, and researchers. HealthLynked provides telemedicine, medical record sharing, discounted prescriptions, and AI-powered health tools to improve outcomes and make care more accessible. With a focus on personalized care and large-scale data insights, HealthLynked empowers individuals to take control of their health while contributing to the advancement of medicine.

To join or learn more, visit www.hlykgroup.com

Download the HealthLynked App:

• Apple App Store
• Google Play Store

Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements are inherently uncertain and may differ materially from actual results. Forward-looking statements reflect management's current expectations and are subject to risks, uncertainties, and assumptions. HealthLynked disclaims any obligation to update these statements except as required by law.

Investor  & MediaContact

HealthLynked Corp.
1265 Creekside Parkway, Suite 200
Naples, FL 34108
Phone: +1 (800) 928-7144
Email: IR@healthlynked.com

View original content:https://www.prnewswire.com/news-releases/healthlynked-launches-national-initiative-to-accelerate-medical-discovery-through-patient-participation-and-strategic-pharma-partnerships-302521002.html

SOURCE HealthLynked Corp.

FAQ

What is HealthLynked's new national initiative announced on August 5, 2025?

HealthLynked announced a nationwide initiative to accelerate medical research by connecting its 1 million+ patient network with pharmaceutical and biotech partners, offering five collaboration tracks for research and development.

How much does HealthLynked's premium membership cost and what does it include?

HealthLynked's premium membership costs $12/month and includes enhanced features, discounted telemedicine services, and priority access to the provider network.

When will HealthLynked's (HLYK) research partnership program be fully available?

The program will be rolled out in phases starting in Q3 2025, expanding in Q4 2025, with full general availability targeted for January 2026.

What are the five partnership tracks offered by HealthLynked for research collaboration?

The five tracks are: 1) Cohort Finder & Feasibility, 2) Recruitment & eConsent, 3) ePROs & RWE Generation, 4) Signal & Safety Monitoring, and 5) Natural History & Rare Disease Registries.

What is ARi in HealthLynked's platform?

ARi is HealthLynked's AI healthcare agent built with OpenAI technologies that analyzes patient data to identify population trends, assist in feasibility modeling, and provide personalized health alerts.